Table 1.

MTX dose, lab results, and reasons for withdrawal

Psoriasis (N=190)Psoriatic arthritis (N=196)
Men, N (%)86 (45.3)95 (48.5)
Age (y), mean (SD)52.3 (16.2)51.8 (13.8)
Prior treatment with MTX8 (4.2)39 (19.9)**
MTX starting dose (mg/week)12.2 (3.7)15.2 (3.0)**
Folic acid starting dose (mg/week)4.9 (0.7)8.4 (5.6)**
Duration of first treatment course (months)19.0 (19.5)34.3 (30.5)**
Laboratory visits per treatment month0.62 (0.81)0.50 (0.34)*
Abnormal lab results per treatment month0.14 (0.26)0.03 (0.07)**
Abnormal lab results per laboratory visit0.26 (0.39)0.06 (0.11)**
Reasons for withdrawal of MTX
 Ineffectiveness46 (24.1%)31 (15.8%)*
 Remission14 (7.3%)21 (10.7%)
 Abnormal laboratory result29 (15.2%)8 (4.1%)**
 Drug toxicity (mild, including infection)47 (24.6%)52 (26.5%)
 Serious Adverse Event2 (1.0%)2 (1.0%)
 Death (not related to MTX)2 (1.0%)4 (2.0%)
 Other22 (11.6%)15 (7.6%)
  • Numbers: mean (SD), *P value ≤0.05; **P-value <0.001 (Fisher's exact test),